Anti-MRSA agent 39

Anti-MRSA agent 39 (Compound 13) (18-72 h) demonstrates potent inhibitory activity against MRSA (MIC = 1 μg/mL) and does not show significant toxicity to human liver cell line LO2 (IC₅₀ = 8.15 μM)^[1].
Anti-MRSA agent 39 (0.25-1 μg/mL, 0-12 h) can rapidly eliminate MRSA in a concentration-dependent manner and reduce the bacterial load to an undetectable level within 12 h at 4 × MIC^[1].
Anti-MRSA agent 39 exhibits a significantly lower propensity for inducing resistance mutations compared to vancomycin^[1].
Anti-MRSA agent 39 (100 μM, 30 min) stabilizes the SaClpX hexamer structure and reduces dimer/trimer formation^[1].
Anti-MRSA agent 39 significantly upregulates ftsZ mRNA expression levels in MRSA ATCC 33591^[1].
Anti-MRSA agent 39 exhibits a 2-4 fold decrease in MIC at 30°C, the "negative temperature coefficient" characteristic consistent with the activity of the ClpX chaperone in MRSA ATCC 33591^[1].
Anti-MRSA agent 39 (0.25-0.5 μg/mL, 1-5 h) elicits profound metabolic dysregulation in MRSA, manifesting as significantly reduced ATP levels, elevated reactive oxygen species (ROS), and decreased NAD+/NADH ratio, and accelerates bacterial lysis rates in MRSA ATCC 33591^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.